menu
    • menu
    [{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Nitric Oxide Innovations","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Nitric Oxide Innovations \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nitric Oxide Innovations \/ Undisclosed"},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nitric Oxide Innovations \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxide Innovations \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Nitric Oxide Innovations

    Menu

    Nitric Oxide Innovations

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nitric Oxide Innovations

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Nitric Oxide Innovations

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Nitrite

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NOi Receives FDA Approval to Begin the Trial on its New Drug NOviricid to Treat COVID 19

                            Details : NOviricid is the first oral NO generating drug to be clinically tested to treat African Americans with COVID-19. NOviricid offers a fast acting, Nitric Oxide therapeutic, with proven vasodilatory and anti-viral properties, targeting the effects of the no...

                            Product Name : NOviricid

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : Sodium Nitrite

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nitric Oxide Innovations

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Nitric Oxide Innovations

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African A...

                            Details : Nitric Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 23, 2020

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth